Over the past five years, Bruker has developed a life science microscopy business that specializes in advanced technologies for neuroscience, live-cell imaging, and molecular imaging, which will be further augmented by JPK’s advanced technologies and applications. Bruker’s existing fluorescence microscopy techniques include performance-leading multiphoton microscopy, swept-field confocal microscopy, super-resolution microscopy, and single-plane illumination microscopy.
“We have been making a substantial investment in advanced technologies for life science imaging, and have built up a portfolio of fluorescence microscopy products that enable biologists in research areas that require deep, fast imaging at high resolution and at low phototoxicity,” commented Dr. Mark R. Munch, President of the Bruker NANO Group. “JPK’s products and applications capabilities nicely augment our current techniques.”
Anthony Finbow, Chairman at JPK, added: “The combination of these two businesses will enable further significant advances in life science imaging and drive the state of the industry. I am delighted that we have been able to achieve this result for JPK and for Bruker.”
“The business we have built aligns well with the new strategic direction of Bruker in life science microscopy, and we are very pleased to join them,” said Dr. Torsten Jaehnke, a JPK founder and CTO. “We plan to realize a number of valuable synergies going forward.”
JPK’s BioAFM and optical tweezer product families span a range of techniques, from imaging of biological samples to characterizing biomolecular and cellular force interactions. Its NanoWizard 4 BioScience AFM combines atomic force imaging with advanced optical fluorescence imaging and super-resolution microscopy for the ultimate combination in image resolution for molecules, membranes, and live cells. In addition, the ForceRobot enables single-molecule force spectroscopy for investigating receptor-ligand interactions or small molecule-protein binding interactions. The CellHesion product brings quantitative force measurement to live cells and tissues, enabling insights in cell-substrate and cell-cell interactions. Lastly, JPK’s NanoTracker optical tweezer provides an all-optical means for molecular and cellular force experiments.
JPK’s offerings and life science applications expertise are synergistic with Bruker’s existing portfolio of advanced fluorescence microscopy products. Bruker’s Ultima family of multiphoton microscopes features proprietary photoactivation and photostimulation capabilities and deeper penetration into biological tissues, enabling advanced brain slice and intra-vital studies. Bruker’s Opterra swept-field scanning confocal fluorescence microscope provides unique live-cell imaging capabilities with unsurpassed dynamic observation of fast cellular events. Additionally, the Vutara super-resolution single-molecule localization (SML) microscope utilizes patented Biplane Imaging technology to provide high-speed, 3D super resolution for multicolor live-cell imaging and visualization of chromosome conformation. With a leading series of single plane illumination products, such as the MuVi SPIM and InVi SPIM, Bruker offers unique performance and easiest-to-use light sheet instruments featuring the combination of low phototoxicity and high-speed imaging. The combined microscopy portfolio of the two companies will enable a unique range of correlative measurements for emerging life science applications.
About Bruker Corporation (NASDAQ: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.
Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
Bruker Nano Surfaces Content Marketing Manager
T: +1 (520) 741-1044 x1022